Evidence map›Paper›PMID 42370281›Full record

ArticleResearch square2026

Asprosin-PTPRD endocrine resistance links brain dysfunction and systemic wasting in Alzheimer's disease.

Bijoya Basu, Hesong Liu, Shrish Pandey, Hiba Obeid, Brennan Flannery, Yinghua Chen, Yuhyun Yun, Andrew Qian, Danica Parfyonov, Qianru Zhao and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Bijoya BasuDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0001-5122-9807
Hesong LiuDepartment of Neuroscience and Physiology, College of Graduate Studies, Upstate Medical University, Syracuse, NY.
Shrish PandeyHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Hiba ObeidDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
Brennan FlanneryDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA.
Yinghua ChenProtein Biophysics and Structure Biology Core Facility, Case Western Reserve University, Cleveland, OH, USA.
Yuhyun YunDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
Andrew QianHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Danica ParfyonovDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.
Qianru ZhaoPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, 70808 USA.
Hailan LiuCenter for Molecular Psychiatry, University of South Florida, Morsani College of Medicine Tampa, FL, USA.
Jingzhi MengHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Gal NavehHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Santosh HanumanthuHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.ORCID 0009-0004-5933-1047
Jennifer HoffmanHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.ORCID 0000-0002-5202-0893
Elizabeth Sabath SilvaHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Jim LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0002-0896-0749
Lynn M BekrisGenomic Medicine Institute Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
C Dirk KeeneDepartment of Pathology, University of Washington School of Medicine, Seattle, WA, USA.ORCID 0000-0002-5291-1469
Juan C BournatDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-0748-2404
Yanlin HePennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA, 70808 USA.ORCID 0000-0002-5471-9016
Ila MishraHarrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.ORCID 0000-0002-9786-6358
Andrew A PieperDepartment of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0001-6299-6577
Yong XuCenter for Molecular Psychiatry, University of South Florida, Morsani College of Medicine Tampa, FL, USA.ORCID 0000-0002-4908-1572
Atul R ChopraDepartment of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA.

Funding

Translational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Christine L MacDonald · 2021 to 2026
$80.4M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
5-HT 2C Receptor and Alzheimer's DiseaseR01AG080392 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI YONG XU · 2023 to 2026
$2.2M
ASPROSIN NEUTRALIZATION AS A NOVEL ANTI-OBESITY TREATMENTR01DK118290 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI CHOPRA, ATUL · 2018 to 2022
$2.0M
The Role of FBN1 in mammalian energy balanceK08DK102529 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI CHOPRA, ATUL · 2014 to 2018
$761k
A 5-HTergic DRN vCA1 circuit and Alzheimer's diseaseK99AG078903 · NIA · BAYLOR COLLEGE OF MEDICINE · PI LIU, HESONG · 2023 to 2024
$224k
NIA NIH HHS K99 AG078903NIA NIH HHS P30 AG066509NIA NIH HHS R01 AG080392NIA NIH HHS U19 AG066567NIDDK NIH HHS K08 DK102529NIDDK NIH HHS R01 DK118290NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by cognitive decline and systemic frailty, but mechanisms linking brain dysfunction to organismal wasting remain unclear. We identify PTPRD, a human-genetically supported regulator of tau pathology, as a high-affinity receptor for amyloid-β (Aβ). Aβ competitively binds the PTPRD extracellular domain, opposing the endogenous ligand asprosin and producing a state of functional signaling insufficiency despite preserved receptor and ligand levels. Circuit-specific

Identifiers

PMID42370281
PMCPMC13308377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.